Home/Pipeline/MDD Clinical Trials

MDD Clinical Trials

Major Depressive Disorder

Not Specified (Typically Phase 2-3)Active

Key Facts

Indication

Major Depressive Disorder

Phase

Not Specified (Typically Phase 2-3)

Status

Active

Company

Boston Clinical Trials

About Boston Clinical Trials

Boston Clinical Trials is a private, revenue-generating clinical research organization (CRO) and site management organization (SMO) based in Roslindale, Massachusetts. Founded in 2008, it has conducted over 300 studies across more than 10 therapeutic areas, primarily focusing on central nervous system disorders, migraines, and other medical specialties. The company's business model is service-based, generating revenue from pharmaceutical and biotech sponsors for patient recruitment, trial execution, and site management. It differentiates itself through patient-centric services like compensation, evening appointments, and a convenient location.

View full company profile

Therapeutic Areas

Neurology Psychiatry Dermatology Gastroenterology Internal Medicine Sexual Dysfunction Urology Migraine

Other Major Depressive Disorder Drugs

Drug	Company	Phase	Status
Accelerated Deep TMS Protocol	BrainsWay	FDA Cleared	Commercializing
ZURZUVAE (zuranolone)	Sage Therapeutics	Phase 3	Deprioritized
NMDAR Antagonist (GM-2505/Bretisilocin)	Gilgamesh Pharmaceuticals	Phase 2	Acquired by AbbVie (2024)
Neuroplastogen (GM-1020)	Gilgamesh Pharmaceuticals	Phase 2a	Active
NA-901	Biomed	Phase 2B/3	Active
SP-624 (Forvisirvat)	Arrivo BioVentures	Phase 2	Active
NBS System for MDD	Nexstim	Approved	Active
Major Depressive Disorder Studies	Noesis Pharma Clinical Trials	Phase 2-4	Active
Depression Studies	Pacific Clinical Research Medical Group	Phase 2/3	Active
Neurotyping Platform for MDD	Universal Brain	Development	Active
CLE-100	Clexio Biosciences	Phase 2	Active
Proliv™Rx	Neurolief	Phase 2	Active